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Drug Safety and Surveillance: the Case of Avandia
Abstract
A year ago, a meta-analysis published in The New England Journal of Medicine sounded alarms about the
cardiovascular safety of the popular diabetes drug Avandia (rosiglitazone). The study caused both
policymakers and the public to question the Food and Drug Administration’s ability to ensure the safety of
drugs brought to the marketplace, and evoked memories of Vioxx, the painkiller withdrawn from the market
in 2004 because of its link to heart attacks. A year after the Avandia story broke, this Clinical Brief revisits the
controversy, summarizes a new study of the cardiovascular safety of diabetes drugs, and analyzes the policy
implications for the drug approval process.
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Editor’s note: A year ago, a meta-analysis published in The New England Journal of
Medicine sounded alarms about the cardiovascular safety of the popular diabetes drug
Avandia (rosiglitazone). The study caused both policymakers and the public to question
the Food and Drug Administration’s ability to ensure the safety of drugs brought to the
marketplace, and evoked memories of Vioxx, the painkiller withdrawn from the market
in 2004 because of its link to heart attacks.  A year after the Avandia story broke, this
Clinical Brief revisits the controversy, summarizes a new study of the cardiovascular
safety of diabetes drugs, and analyzes the policy implications for the drug approval
process.
Avandia was first marketed in 1999 as an oral treatment for Type 2 diabetes.  It was
adopted quickly, becoming the top selling oral diabetes drug in the U.S. in 2006.
Avandia, and its sister drug Actos (pioglitazone), belong to the drug class
thiazolidinediones (TZDs), which reduce insulin resistance. [The first TZD, Rezulin
(troglitazone) was removed from the market for causing liver disease.] TZDs can be used
alone or with other hypoglycemic drugs to improve glycemic control in diabetic patients.
• As with other diabetes drugs, Avandia was approved for marketing on the basis of its
ability to lower blood glucose. Its effects on longer-term outcomes, such as microvas-
cular complications or cardiovascular disease, were unknown. Premarketing studies
were not designed to examine these outcomes.
• Because TZDs can cause fluid retention, Avandia was not recommended for patients
with symptomatic heart failure.  In August 2007 the FDA requested that both
Avandia and Actos carry a stronger “black box” warning against its use in patients
with heart failure.
• After approval, some signals suggested that Avandia might increase the risk of myocar-
dial ischemia that might lead to heart attacks, but the evidence was inconclusive. A
post-marketing clinical safety trial of 4,400 patients was eventually launched, with
results to be available in 2009.  In May 2007, a meta-analysis combining the results of
42 clinical trials of Avandia found a 43% percent increased risk of heart attack among
patients taking the drug, mostly compared to a placebo.  However, the analysis
combined studies of various designs and goals, and included some studies of non-
diabetic patients.  The article prompted the FDA to convene a panel to review the
evidence and recommend any action.
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• In July 2007, the panel acknowledged the possibility of elevated risk of heart attacks
with Avandia, especially when used in combination with insulin, but voted over-
whelmingly to keep the drug on the market.  In November 2007, Avandia’s labeling
was changed to include the results of the meta-analysis, as well as the FDA’s determi-
nation that there was not enough evidence that Avandia posed an increased risk for
myocardial ischemia, especially compared to other approved drugs to manage diabetes.
To compare cardiovascular outcomes associated with different diabetes treatments,
Margolis and colleagues used The Health Information Network (THIN), a medical
records system set up in 2002 in the United Kingdom.  THIN contains records from
about 300 UK general practices, and includes 4.78 million patients, of which 2.26
million are currently active. The investigators identified patients with at least two records
for Type 2 diabetes between January 2002 and January 2006 who were at least 40 years
old.
• The investigators studied two cohorts within the database: individuals diagnosed with
diabetes at any time, and a sub-cohort of those diagnosed after 2002.  There were
63,579 individuals in the first cohort, with median diabetes duration of 6.5 years, and
13,576 in the sub-cohort.
• The primary outcome of interest was the onset of serious cardiovascular disease after
exposure to an oral diabetic medication.  These outcomes included myocardial
infarction, unstable angina, cardiac death, as well as coronary artery procedures such
as angioplasty or bypass surgery.
• The investigators adjusted for confounding factors such as age, sex, body mass index,
and prior history of cardiovascular disease.
Overall, the analysis revealed that diabetic patients using TZDs had a lower risk of
myocardial infarction and other myocardial ischemic events, compared to users of other
therapies used to treat diabetes. Conversely, those who used insulin and sulfonylureas
had a higher risk of myocardial infarction, a risk that emerged or increased with longer
use.
• Of the 63,579 individuals in the long-term cohort, 5,644 experienced one of the
cardiovascular outcomes.  After adjusting for other factors, the investigators found an
increased risk of serious cardiovascular disease associated with insulin (hazard ratio,
1.2) and decreased risk associated with both TZDs (hazard ratio, 0.5).
• Of the 13,576 individuals in the more recently diagnosed cohort, 744 experienced
one of the cardiovascular outcomes. After adjusting for other factors, the investigators
found an increased risk of serious cardiovascular disease associated with insulin
(hazard ratio, 2.4), sulfonylureas (hazard ratio, 1.4) and decreased risk associated with
both TZDs (hazard ratio, 0.8).
• Risk increased as total duration of therapy increased for insulin, sulfonylureas, and
biguanide, but decreased with duration for both TZDs.  No additional risk was
associated with combinations of drugs.
• This study does not definitively answer whether Avandia increases or decreases the
risk of cardiovascular events, but it does emphasize that careful studies are necessary
after a drug is marketed to learn about unexpected risks.
New study compares
cardiovascular outcomes
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heart attacks found with
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In June 2007, Strom submitted testimony about the Avandia controversy to a Congres-
sional oversight committee.  In it, he discussed the scientific issues of Avandia safety
regarding myocardial infarction, and cautioned against an exaggerated response to the
meta-analysis.
• Strom said that the meta-analysis raised a signal of concern, but that other available
studies had not confirmed the findings.  He noted that the post-marketing trial was
underway to more definitively answer the question, and that the FDA, physicians,
and patients could reasonably await these results.  He also mentioned the significant
risk to patients of quickly withdrawing a drug that was helping to control their blood
glucose.
• Strom emphasized that many adverse reactions will not be known at the time of
approval, and that such a situation is not evidence that the FDA has failed. Generally,
a drug is studied in roughly 2000-3000 patients before approval—meaning that
adverse reactions that occur once per 100 patients will be known at the time of
marketing.  In contrast, adverse reactions that occur once per 1000 patients will not
be known at the time of marketing. “The problem is that these studies take a long
time to conduct, and we have to ask whether we should deny patients access to the
drug while these studies are underway. My view is that these studies should be done,
and the drugs should be available while they are being done, but only selectively to
patients that really need them. The situation we have now is that new drugs are
overused too early.”
The Avandia controversy highlights the holes in the U.S. drug safety system, which does
not accommodate the need for studies after a drug is marketed.  Until recently, the FDA
did not have the regulatory or enforcement authority to require such data.  Pharmaceuti-
cal manufacturers have little incentive to provide these data.  Strom outlined his vision
of systemic changes that would improve the ability of the FDA to ensure drug safety.
• Conditional approval.  Initial drug approval should at first be conditional. During
this time, marketing, especially direct-to-consumer marketing, should be restricted.
Conditional approval would be removed only when sufficient numbers of individuals
have been investigated to ensure the detection of rare side effects and to answer drug
safety questions that emerged pre-marketing or thereafter. This way, drug use immedi-
ately after marketing would be restricted to those who truly need the drug, in whom
the risk/benefit balance in the face of uncertainty is more favorable.
• Empowered FDA.  Strom and others noted that the FDA could not require post-
marketing studies or labeling changes; rather, any changes were subject to negotiation
between the FDA and the manufacturer.  Congress addressed this issue in September
2007, at least in part, when it gave the FDA the regulatory authority to require post-
marketing data, enforcement authority to fine manufacturers if necessary, and new
resources set aside for drug safety.
At this point, the link between Avandia and ischemic cardiac outcomes remains un-
known.  The results of the meta-analysis that raised public concerns have not been
confirmed by subsequent studies.  The new study described in this brief, although
retrospective in nature, found a reduced risk associated with Avandia.  While the
Avandia question remains unsettled, the episode does serve as a cautionary tale about
existing flaws in the system.
Drug safety in perspective
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• Congress and the public must be given a better perspective on the benefits and risks
from pharmaceutical products. Drugs are not without risk, and a drug’s balance of
risks and benefits becomes less favorable as the drug is marketed to wider populations
with less specific need. Many risks can be determined only after a drug is marketed to
these wider populations.
• The system must provide pharmaceutical manufacturers with incentives to provide
postmarketing information, rather than disincentives. A conditional approval designa-
tion would prompt drug sponsors to gather post-marketing safety information
quickly.
• The FDA should fully use its new regulatory authority to address some of the post-
marketing safety questions that will inevitably arise. The additional resources devoted
to drug safety, while critically important, remain inadequate. In 2008, the FDA will
collect an additional $25 million in user fees (from the drug industry) for post-
marketing safety, which will increase by $10 million per year through 2012. The
Institute of Medicine estimates that 10 safety signals per year could be evaluated
extramurally at an annual cost of $10-$60 million. The FDA’s budget increase is
dwarfed by the $188.5 billion spent on prescription drugs in the U.S. in 2004 and
the $11.9 billion spent on pharmaceutical advertising in the same year.
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